HUHenrietta Onyinye Uzoeto

Henrietta Onyinye Uzoeto

*This is an algorithmically generated author record based on publicly available information.

Henrietta Onyinye Uzoeto has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genotypic Diversity and Multidrug Resistance Profiles of AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Abakaliki, Nigeria

    by Henrietta Uzoeto, Ismaila Danjuma Mohammed, Ugonna Cassandra Aniokete, Ikemesit Udeme Peter

    Background: This study investigated the genotypic diversity and multidrug resistance profiles of plasmid-mediated AmpC (pAmpC)-producing Escherichia coli and Klebsiella pneumoniae isolated from clinical samples at AE-FUTHA, Nigeria. Methods: A total of 200 clinical samples (140 urine and 60 wound swabs) were collected from patients at AE-FUTHA. Phenotypic detection of AmpC β-lactamases was performed using the cefoxitin-cloxacillin double-disk synergy test (CC-DDST). All phenotypically confirmed AmpC-producing isolates were subjected to antimicrobial susceptibility testing using the Kirby-Bauer disk diffusion method against 10 antibiotics from seven classes. Multiplex PCR was used to detect six pAmpC gene families (blaFOX, blaEBC, blaDHA, blaCIT, blaACC, and blaMOX) in all phenotypic AmpC producers. Results: A total of 72 bacterial isolates comprising 51 (70.8%) E. coli and 21 (29.2%) K. pneumoniae were recovered. Phenotypic AmpC production was detected in 67 (93.1%) isolates, with a significantly higher prevalence in K. pneumoniae (100%) compared to E. coli (90.2%) (p=0.04). All 67 AmpC-producing isolates (100%) exhibited multidrug resistance (MDR) with MAR indices ranging from 0.3-0.7. High-level resistance was observed to β-lactams: and the β-lactam/β-lactamase inhibitor combination (100%). Resistance to the monobactam aztreonam was 95.5%, while the folate pathway inhibitor trimethoprim-sulfamethoxazole showed 98.5% resistance. The carbapenem imipenem remained highly effective (97.0% susceptibility), followed by the aminoglycoside amikacin (89.6%) and the fluoroquinolone ofloxacin (82.1%). The blaFOX gene was present in 100% of E. coli but only 52.4% of K. pneumoniae isolates (p<0.001). Co-carriage of all six pAmpC gene families was observed in 52.4% of K. pneumoniae and 100% of E. coli isolates. Significant associations were found between sample source and blaFOX carriage in K. pneumoniae (p=0.002). Conclusion: This study reveals a remarkably high prevalence of genotypically diverse pAmpC genes with alarming MDR profiles among clinical E. coli and K. pneumoniae isolates in Abakaliki, Nigeria. The universal co-carriage of five pAmpC gene families and species-specific distribution of blaFOX highlight the complex molecular epidemiology of resistance in this setting. The sustained efficacy of carbapenems, amikacin, and ofloxacin provides therapeutic options, but urgent antimicrobial stewardship and infection control measures are required to prevent further spread of these resistance determinants.

  • Open Access

    Exploring the potential of aqueous extracts of Artemisia annua ANAMED (A3) for developing new anti‐malarial agents: In vivo and silico computational approach

    by Victor Onukwube Apeh, Kennedy Chinedu Okafor, Ifeoma Felicia Chukwuma, Henrietta Onyinye Uzoeto, Titus Ifeanyi Chinebu, Florence Nkechi Nworah, Emmanuel Israel Edache, Ijeoma Peace Okafor, Okoronkwo Chukwunenye Anthony

    The emergence of resistance to current antimalarial drugs poses a significant challenge in the fight against malaria. This study aimed to investigate the in vivo antiplasmodial potential of the aqueous extract of fresh and dried leaves of A3 in Plasmodium berghei‐infected (P. berghei) mice. A 4‐day suppressive test was conducted, with infected BALB/c mice receiving artesunate and A3 extracts. The results showed that the tested doses of A3 attenuated the elevation of parasitemia induced by P. berghei, particularly at the dose of 400 mg/kg, and improved hematological indices. Computational techniques, including molecular docking, binding free energy calculations, and ADMET predictions, identified several bioactive compounds in A3 with promising inhibitory potential against lysyl‐tRNA synthetases and Dihydrofolate reductase (DHFR), the crucial enzymes targeted by antimalarial drugs. In this paper, Friedelin, Bauerenol, Epifriedelanol, Alpha‐Amyrenone, Stigmasterol, and beta‐Amyrin acetate were top‐ranked, having docking scores from −10.6 to −9.9 kcal/mol, compared with the −9.4 and −7.1 kcal/mol demonstrated by artesunate and chloroquine, respectively, as standard ligands. Also, it was shown that docking score from the Lysyl‐tRNA protein target (4YCV) ranged from −9.5 to −7.8 kcal/mol in comparison to artesunate (8.1 kcal/mol) and chloroquine (5.6 kcal/mol). The results suggest that the identified compounds in A3 could serve as potential candidates for the development of new anti‐malarial agents.


  • Open Access

    Molecular characterization of Enterobacteriacea isolated from gingivitis and periodontitis patients and the antimicrobial activity of mouth wash agents

    by I R Iroha, I D Mohammed, I B Moses, N J Ngwu, H O Uzoeto, A S Oladimeji, U P Ikemesit, L A Onuora, N J Ewa, C.I. Edemekong